Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19
MD, MPH Wesley H Self, MD; Matthew W Semler, DO; Lindsay M Leither, MD, MSc Jonathan D Casey, MD, MPH Derek C Angus, MD Roy G Brower, MD, PhD Steven Y Chang, MD; Sean P Collins, MD John C Eppensteiner, MD Michael R Filbin, D Clark Files, MD Kevin W Gibbs, MD, MPH Adit A Ginde, MD Michelle N Gong, MS Frank E Harrell Jr, PhD Douglas L Hayden, MD, MSc Catherine L Hough, MD Nicholas J Johnson, MD Akram Khan, PhD Christopher J Lindsell, MD Michael A Matthay, MD Marc Moss, MD Pauline K Park, MD Todd W Rice, MD Bryce R H Robinson, MS David A Schoenfeld, PhD Nathan I Shapiro, MD, MPH Jay S Steingrub, MD Christine A Ulysse, MS Alexandra Weissman, MD, MPH Donald M Yealy, B Taylor Thompson, MD; Samuel M Brown
JAMA, doi:10.1001/jama.2020.22240
OBJECTIVE To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients. INTERVENTIONS Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237).
MAIN OUTCOMES AND MEASURES The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality. RESULTS Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, −0.2% [95% CI, −5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). CONCLUSIONS AND RELEVANCE Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.
Author Contributions: Drs Schoenfeld and Hayden had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Schoenfeld and Self take responsibility for the trial overall. Conflict of Interest Disclosures: Dr Self reported receiving grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study and personal fees from Aerpio Pharmaceuticals outside the submitted work. Dr Semler reported receiving grants from the NHLBI during the conduct of the study. Dr Leither reported receiving grants from the NHLBI during the conduct of the study. Dr Casey reported receiving grants from the NHLBI during the conduct of the study. Dr Angus reported receiving grants from the NHLBI and National Center for Advancing Translational Sciences (NCATS) during the conduct of the study and personal fees from Ferring Pharmaceuticals, Bristol-Myers Squibb, and Bayer AG and stock from Alung Technologies. Dr Angus has patents pending through Ferring Pharmaceuticals and the University of Pittsburgh. Dr Chang reported receiving grants from the NHLBI during the conduct of the study and personal fees from PureTech Health and LaJolla Pharmaceuticals outside the submitted work. Dr Collins reported receiving grants from the NHLBI and personal fees from Vir Biotechnology outside the submitted U01HL123020). The REDCap data tools used for this study were supported by a grant from NCATS..
References
Administrative, Self, Semler, Casey, Angus et al., Supervision: Self
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19: preliminary report: reply, N Engl J Med,
doi:10.1056/NEJMoa2007764Casey, Johnson, Semler, Rationale and design of ORCHID: a randomized placebo-controlled clinical trial of hydroxychloroquine for adults hospitalized with COVID-19, Ann Am Thorac Soc,
doi:10.1513/AnnalsATS.202005-478SDCavalcanti, Zampieri, Rosa, Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2019014Concept, Self, Semler, Angus, Casey et al., Critical revision of the manuscript for important intellectual content
Derwand, Scholz, Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Med Hypotheses,
doi:10.1016/j.mehy.2020.109815Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1186/s13054-020-03194-wHerdman, Gudex, Lloyd, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res,
doi:10.1007/s11136-011-9903-xHoffmann, Mösbauer, Hofmann-Winkler, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature,
doi:10.1038/s41586-020-2575-3Horby, Mafham, Linsell, Effect of hydroxychloroquine in hospitalized patients with COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2022926Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0Mercuro, Yen, Shim, Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease
Rl, Shumaker, Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19, Clin Infect Dis,
doi:10.1093/cid/ciaa478Rubin, Harrington, Hogan, Gatsonis, Baden et al., The urgency of care during the COVID-19 pandemic: learning as we go, N Engl J Med,
doi:10.1056/NEJMe2015903Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol,
doi:10.1038/s41584-020-0372-xWang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0Wang, Lagakos, Ware, Hunter, Drazen, Statistics in medicine: reporting of subgroup analyses in clinical trials, N Engl J Med,
doi:10.1056/NEJMsr077003Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis,
doi:10.1093/cid/ciaa237Yehya, Harhay, Curley, Schoenfeld, Reeder, Reappraisal of ventilator-free days in critical care research, Am J Respir Crit Care Med,
doi:10.1164/rccm.201810-2050CPDOI record:
{
"DOI": "10.1001/jama.2020.22240",
"ISSN": [
"0098-7484"
],
"URL": "http://dx.doi.org/10.1001/jama.2020.22240",
"author": [
{
"affiliation": [
{
"name": "Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"
}
],
"family": "Self",
"given": "Wesley H.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"
}
],
"family": "Semler",
"given": "Matthew W.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"
},
{
"name": "University of Utah, Salt Lake City"
}
],
"family": "Leither",
"given": "Lindsay M.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"
}
],
"family": "Casey",
"given": "Jonathan D.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"
}
],
"family": "Angus",
"given": "Derek C.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"
}
],
"family": "Brower",
"given": "Roy G.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Ronald Reagan–UCLA Medical Center, Los Angeles, California"
}
],
"family": "Chang",
"given": "Steven Y.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"
}
],
"family": "Collins",
"given": "Sean P.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Surgery, Duke University, Durham, North Carolina"
}
],
"family": "Eppensteiner",
"given": "John C.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, Massachusetts General Hospital, Boston"
}
],
"family": "Filbin",
"given": "Michael R.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Section of Pulmonary, Critical Care, Allergy and Immunologic Disease, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"
}
],
"family": "Files",
"given": "D. Clark",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Section of Pulmonary, Critical Care, Allergy and Immunologic Disease, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina"
}
],
"family": "Gibbs",
"given": "Kevin W.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, University of Colorado School of Medicine, Aurora"
}
],
"family": "Ginde",
"given": "Adit A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Epidemiology and Population Health, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York"
}
],
"family": "Gong",
"given": "Michelle N.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"
}
],
"family": "Harrell",
"given": "Frank E.",
"sequence": "additional",
"suffix": "Jr"
},
{
"affiliation": [
{
"name": "Department of Medicine, Massachusetts General Hospital, Boston"
}
],
"family": "Hayden",
"given": "Douglas L.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland"
}
],
"family": "Hough",
"given": "Catherine L.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine and Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle"
}
],
"family": "Johnson",
"given": "Nicholas J.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health and Science University School of Medicine, Portland"
}
],
"family": "Khan",
"given": "Akram",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"
}
],
"family": "Lindsell",
"given": "Christopher J.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Cardiovascular Research Institute, Departments of Medicine and Anesthesia, University of California, San Francisco"
}
],
"family": "Matthay",
"given": "Michael A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora"
}
],
"family": "Moss",
"given": "Marc",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Surgery, University of Michigan, Ann Arbor"
}
],
"family": "Park",
"given": "Pauline K.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"
}
],
"family": "Rice",
"given": "Todd W.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Surgery, University of Washington, Seattle"
}
],
"family": "Robinson",
"given": "Bryce R. H.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Medicine, Massachusetts General Hospital, Boston"
}
],
"family": "Schoenfeld",
"given": "David A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"
}
],
"family": "Shapiro",
"given": "Nathan I.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Medicine, University of Massachusetts Medical School-Baystate, Springfield"
}
],
"family": "Steingrub",
"given": "Jay S.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Medicine, Massachusetts General Hospital, Boston"
}
],
"family": "Ulysse",
"given": "Christine A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"
}
],
"family": "Weissman",
"given": "Alexandra",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania"
}
],
"family": "Yealy",
"given": "Donald M.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston"
}
],
"family": "Thompson",
"given": "B. Taylor",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah"
},
{
"name": "University of Utah, Salt Lake City"
}
],
"family": "Brown",
"given": "Samuel M.",
"sequence": "additional"
},
{
"affiliation": [],
"name": "National Heart, Lung, and Blood Institute PETAL Clinical Trials Network",
"sequence": "additional"
}
],
"container-title": "JAMA",
"container-title-short": "JAMA",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
11,
9
]
],
"date-time": "2020-11-09T11:00:28Z",
"timestamp": 1604919628000
},
"deposited": {
"date-parts": [
[
2020,
12,
1
]
],
"date-time": "2020-12-01T12:52:29Z",
"timestamp": 1606827149000
},
"indexed": {
"date-parts": [
[
2024,
4,
6
]
],
"date-time": "2024-04-06T10:31:34Z",
"timestamp": 1712399494266
},
"is-referenced-by-count": 310,
"issue": "21",
"issued": {
"date-parts": [
[
2020,
12,
1
]
]
},
"journal-issue": {
"issue": "21",
"published-print": {
"date-parts": [
[
2020,
12,
1
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://jamanetwork.com/journals/jama/articlepdf/2772922/jama_self_2020_oi_200119_1606767652.12648.pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "10",
"original-title": [],
"page": "2165",
"prefix": "10.1001",
"published": {
"date-parts": [
[
2020,
12,
1
]
]
},
"published-print": {
"date-parts": [
[
2020,
12,
1
]
]
},
"publisher": "American Medical Association (AMA)",
"reference": [
{
"DOI": "10.1016/j.ijantimicag.2020.105982",
"article-title": "Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies.",
"author": "Zhao",
"doi-asserted-by": "crossref",
"issue": "6",
"journal-title": "Int J Antimicrob Agents",
"key": "joi200119r3",
"volume": "55",
"year": "2020"
},
{
"DOI": "10.1038/s41584-020-0372-x",
"article-title": "Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.",
"author": "Schrezenmeier",
"doi-asserted-by": "publisher",
"first-page": "155",
"issue": "3",
"journal-title": "Nat Rev Rheumatol",
"key": "joi200119r4",
"volume": "16",
"year": "2020"
},
{
"article-title": "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review.",
"author": "Sanders",
"first-page": "1824",
"issue": "18",
"journal-title": "JAMA",
"key": "joi200119r5",
"volume": "323",
"year": "2020"
},
{
"DOI": "10.1038/s41422-020-0282-0",
"article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.",
"author": "Wang",
"doi-asserted-by": "publisher",
"first-page": "269",
"issue": "3",
"journal-title": "Cell Res",
"key": "joi200119r6",
"volume": "30",
"year": "2020"
},
{
"DOI": "10.1093/cid/ciaa237",
"article-title": "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).",
"author": "Yao",
"doi-asserted-by": "publisher",
"first-page": "732",
"issue": "15",
"journal-title": "Clin Infect Dis",
"key": "joi200119r7",
"volume": "71",
"year": "2020"
},
{
"DOI": "10.1038/s41421-020-0156-0",
"article-title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.",
"author": "Liu",
"doi-asserted-by": "publisher",
"first-page": "16",
"journal-title": "Cell Discov",
"key": "joi200119r8",
"volume": "6",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.",
"author": "Gautret",
"doi-asserted-by": "crossref",
"issue": "1",
"journal-title": "Int J Antimicrob Agents",
"key": "joi200119r9",
"volume": "56",
"year": "2020"
},
{
"DOI": "10.1186/s13054-020-03194-w",
"article-title": "International variation in the management of severe COVID-19 patients.",
"author": "Azoulay",
"doi-asserted-by": "publisher",
"first-page": "486",
"issue": "1",
"journal-title": "Crit Care",
"key": "joi200119r10",
"volume": "24",
"year": "2020"
},
{
"article-title": "Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19.",
"author": "Bhimraj",
"journal-title": "Clin Infect Dis",
"key": "joi200119r14"
},
{
"DOI": "10.1056/NEJMe2015903",
"article-title": "The urgency of care during the COVID-19 pandemic: learning as we go.",
"author": "Rubin",
"doi-asserted-by": "publisher",
"first-page": "2461",
"issue": "25",
"journal-title": "N Engl J Med",
"key": "joi200119r15",
"volume": "382",
"year": "2020"
},
{
"DOI": "10.1513/AnnalsATS.202005-478SD",
"article-title": "Rationale and design of ORCHID: a randomized placebo-controlled clinical trial of hydroxychloroquine for adults hospitalized with COVID-19.",
"author": "Casey",
"doi-asserted-by": "publisher",
"first-page": "1144",
"issue": "9",
"journal-title": "Ann Am Thorac Soc",
"key": "joi200119r16",
"volume": "17",
"year": "2020"
},
{
"DOI": "10.1161/CIRCULATIONAHA.120.047521",
"article-title": "Considerations for drug interactions on QTc in exploratory COVID-19 treatment.",
"author": "Roden",
"doi-asserted-by": "publisher",
"first-page": "e906",
"issue": "24",
"journal-title": "Circulation",
"key": "joi200119r17",
"volume": "141",
"year": "2020"
},
{
"DOI": "10.1001/jamacardio.2020.1834",
"article-title": "Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19).",
"author": "Mercuro",
"doi-asserted-by": "publisher",
"first-page": "1036",
"issue": "9",
"journal-title": "JAMA Cardiol",
"key": "joi200119r18",
"volume": "5",
"year": "2020"
},
{
"DOI": "10.1016/0168-8510(90)90421-9",
"article-title": "EuroQol: a new facility for the measurement of health-related quality of life.",
"author": "EuroQol Group",
"doi-asserted-by": "publisher",
"first-page": "199",
"issue": "3",
"journal-title": "Health Policy",
"key": "joi200119r20",
"volume": "16",
"year": "1990"
},
{
"DOI": "10.1007/s11136-011-9903-x",
"article-title": "Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).",
"author": "Herdman",
"doi-asserted-by": "publisher",
"first-page": "1727",
"issue": "10",
"journal-title": "Qual Life Res",
"key": "joi200119r21",
"volume": "20",
"year": "2011"
},
{
"DOI": "10.1164/rccm.201810-2050CP",
"article-title": "Reappraisal of ventilator-free days in critical care research.",
"author": "Yehya",
"doi-asserted-by": "publisher",
"first-page": "828",
"issue": "7",
"journal-title": "Am J Respir Crit Care Med",
"key": "joi200119r22",
"volume": "200",
"year": "2019"
},
{
"DOI": "10.1001/jama.2016.0287",
"article-title": "The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).",
"author": "Singer",
"doi-asserted-by": "publisher",
"first-page": "801",
"issue": "8",
"journal-title": "JAMA",
"key": "joi200119r23",
"volume": "315",
"year": "2016"
},
{
"DOI": "10.1056/NEJMsr077003",
"article-title": "Statistics in medicine: reporting of subgroup analyses in clinical trials.",
"author": "Wang",
"doi-asserted-by": "publisher",
"first-page": "2189",
"issue": "21",
"journal-title": "N Engl J Med",
"key": "joi200119r24",
"volume": "357",
"year": "2007"
},
{
"DOI": "10.1080/01621459.1999.10474144",
"article-title": "A proportional hazards model for the subdistribution of a competing risk.",
"author": "Fine",
"doi-asserted-by": "publisher",
"first-page": "496",
"issue": "446",
"journal-title": "J Am Stat Assoc",
"key": "joi200119r25",
"volume": "94",
"year": "1999"
},
{
"DOI": "10.1038/s41586-020-2558-4",
"article-title": "Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.",
"author": "Maisonnasse",
"doi-asserted-by": "publisher",
"first-page": "584",
"issue": "7826",
"journal-title": "Nature",
"key": "joi200119r31",
"volume": "585",
"year": "2020"
},
{
"DOI": "10.1038/s41586-020-2575-3",
"article-title": "Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.",
"author": "Hoffmann",
"doi-asserted-by": "publisher",
"first-page": "588",
"issue": "7826",
"journal-title": "Nature",
"key": "joi200119r32",
"volume": "585",
"year": "2020"
},
{
"article-title": "Effect of hydroxychloroquine in hospitalized patients with COVID-19.",
"author": "Horby",
"journal-title": "N Engl J Med",
"key": "joi200119r33",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2019014",
"article-title": "Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19.",
"author": "Cavalcanti",
"doi-asserted-by": "crossref",
"journal-title": "N Engl J Med",
"key": "joi200119r34",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.16349",
"article-title": "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial.",
"author": "Spinner",
"doi-asserted-by": "publisher",
"first-page": "1048",
"issue": "11",
"journal-title": "JAMA",
"key": "joi200119r35",
"volume": "324",
"year": "2020"
},
{
"article-title": "Remdesivir for the treatment of COVID-19: preliminary report: reply.",
"author": "Beigel",
"first-page": "994",
"issue": "10",
"journal-title": "N Engl J Med",
"key": "joi200119r36",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1016/j.mehy.2020.109815",
"article-title": "Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19?",
"author": "Derwand",
"doi-asserted-by": "crossref",
"journal-title": "Med Hypotheses",
"key": "joi200119r37",
"volume": "142",
"year": "2020"
},
{
"key": "joi200119r1",
"unstructured": "Johns Hopkins University. Coronavirus resource center. Accessed July 28, 2020. https://coronavirus.jhu.edu/map.html"
},
{
"key": "joi200119r2",
"unstructured": "World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Accessed September 22, 2020. https://covid19.who.int/"
},
{
"key": "joi200119r11",
"unstructured": "Massachusetts General Hospital. Massachusetts General Hospital COVID-19 treatment guidance. Accessed May 8, 2020. https://web.archive.org/web/20200410013441/https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf"
},
{
"key": "joi200119r12",
"unstructured": "Vanderbilt University Medical Center. Clinical recommendations for treatment of COVID-19 adult patients. Accessed March 13, 2020. https://www.vumc.org/coronavirus/sites/default/files/COVID%20Documents/VUMC%20interim%20recommendations%20for%20clinical%20care%20of%20COVID%20patients%203.14.2020%20final.pdf"
},
{
"key": "joi200119r13",
"unstructured": "National Institutes of Health (NIH). Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed June 30, 2020. https://www.covid19treatmentguidelines.nih.gov"
},
{
"key": "joi200119r19",
"unstructured": "World Health Organization. WHO R&D blueprint: novel coronavirus: COVID-19 therapeutic trial synopsis. Accessed June 28, 2020. https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf"
},
{
"key": "joi200119r26",
"unstructured": "RECOVERY Investigators. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19: statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. Accessed June 28, 2020. https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19"
},
{
"key": "joi200119r27",
"unstructured": "Food and Drug Administration (FDA). Fact sheet for healthcare providers: emergency use authorization (EUA) of Veklury (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. Accessed October 8, 2020. https://www.fda.gov/media/137566/download"
},
{
"key": "joi200119r28",
"unstructured": "Medicines and Healthcare Products Regulatory Agency. MHRA suspends recruitment to COVID-19 hydroxychloroquine trials. Accessed October 10, 2020. https://www.gov.uk/government/news/mhra-suspends-recruitment-to-covid-19-hydroxychloroquine-trials"
},
{
"key": "joi200119r29",
"unstructured": "Food and Drug Administration (FDA). Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 coronavirus disease. Accessed July 2, 2020. https://www.fda.gov/media/136534/download"
},
{
"key": "joi200119r30",
"unstructured": "Food and Drug Administration (FDA). Letter revoking EUA for chloroquine phosphate and hydroxychloroquine sulfate. Accessed July 2, 2020. https://www.fda.gov/media/138945/download"
}
],
"reference-count": 37,
"references-count": 37,
"relation": {},
"resource": {
"primary": {
"URL": "https://jamanetwork.com/journals/jama/fullarticle/2772922"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"General Medicine"
],
"subtitle": [
"A Randomized Clinical Trial"
],
"title": "Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19",
"type": "journal-article",
"volume": "324"
}
